1.Fletcher RH, Fletcher SW, Fletcher GS. Clinical epidemiology: the essentials: Lippincott Williams & Wilkins; 2012.
2.Coggon D, Barker D, Rose G. Epidemiology for the Uninitiated: John Wiley & Sons; 2009.
3.Munn Z, Moola S, Riitano D, Lisy K. The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. International journal of health policy and management. 2014;3(3):123.
4.Munn Z, Moola S, Riitano D, Lisy K. The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. Int J Health Policy Manag. 2014;3(3):123–8.
5.Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Systematic reviews of prevalence and incidence. In: Aromataris E, Munn Z, editors. Joanna Briggs Institute Reviewer’s Manual: The Joanna Briggs Institute; 2017.
6.Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical research ed). 2009;339:b2700.
7.Wells G, Shea B, O’connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa (ON): Ottawa Hospital Research Institute; 2009. Available in March. 2016.
8.Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Annals of internal medicine. 2007;147(8):573–7.
9.Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Annals of internal medicine. 2018;169(7):467–73.
10.McInnes MD, Moher D, Thombs BD, McGrath TA, Bossuyt PM, Clifford T, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. Jama. 2018;319(4):388–96.
11.Munn Z, Moola S, Lisy K, Riitano D. The synthesis of prevalence and incidence data. Pearson A, editor. Philadelphia: Lippincott Williams & Wilkins; 2014.
12.Iorio A, Stonebraker JS, Chambost H, Makris M, Coffin D, Herr C, et al. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National RegistriesMale Prevalence and Prevalence at Birth of Hemophilia. Annals of Internal Medicine. 2019.
13.Rao SR, Graubard BI, Schmid CH, Morton SC, Louis TA, Zaslavsky AM, et al. Meta-analysis of survey data: application to health services research. Health Services and Outcomes Research Methodology. 2008;8(2):98–114.
14.Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. Journal of epidemiology and community health. 2013;67(11):974–8.
15.Jablensky A. Schizophrenia: the epidemiological horizon. In: Hirsch S, Weinberger D, editors. Schizophrenia. Oxford:: Black-well Science; 2003. p. 203–31.
16.Saha S, Chant D, McGrath J. Meta-analyses of the incidence and prevalence of schizophrenia: conceptual and methodological issues. International journal of methods in psychiatric research. 2008;17(1):55–61.
17.Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc. 2015;13(3):147–53.
18.Schwarzer G, Chemaitelly H, Abu‐Raddad LJ, Rücker G. Seriously misleading results using inverse of Freeman‐Tukey double arcsine transformation in meta‐analysis of single proportions. Research synthesis methods. 2019.
19.Rücker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I 2 in assessing heterogeneity may mislead. BMC medical research methodology. 2008;8(1):79.
20.Borenstein M, Higgins JP, Hedges LV, Rothstein HR. Basics of meta‐analysis: I2 is not an absolute measure of heterogeneity. Research synthesis methods. 2017;8(1):5–18.
21.Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ. What is “quality of evidence” and why is it important to clinicians? BMJ. 2008;336(7651):995.
22.Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924.
23.Iorio A, Spencer FA, Falavigna M, Alba C, Lang E, Burnand B, et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ: British Medical Journal. 2015;350:h870.
24.Munn Z, Aromataris E, Tufanaru C, Stern C, Porritt K, Farrow J, et al. The development of software to support multiple systematic review types: the Joanna Briggs institute system for the unified management, assessment and review of information (JBI SUMARI). International journal of evidence-based healthcare. 2019;17(1):36–43.
25.Stern C, Munn Z, Porritt K, Lockwood C, Peters MD, Bellman S, et al. An international educational training course for conducting systematic reviews in health care: the Joanna Briggs Institute’s comprehensive systematic review training program. Worldviews on Evidence‐Based Nursing. 2018;15(5):401–8.